Funding This work was supported by Board of Research in Nuclear Sciences (BRNS) (37(1)/14/57/2014-BRNS), Department of Atomic Energy (DAE), Government of India
Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope, or lower extremity edema
Furthermore, NaBPC157 reduced MPTP-motor abnormalities (tremor, akinesia, catalepsy, otherwise very prominent in saline control) leading to an almost complete abolition of the normally lethal course of MPTP treatment in controls
Note what the symptom is, when it started, how intense it feels, and how long it lasts
19 MaB.LeijtenJ
For parties residing outside of the U.S., this information is: (i) provided for informational purposes only, (ii) not and should not be construed in any manner as an offer to participate in any investment or to buy or sell any securities or related financial instruments, and (iii) not and should not be construed in any manner as a public offering of any financial services, securities or related financial instruments
